Recordati reported a strong nine-month performance for 2025, with consolidated revenue up 12.2% to €1.96 billion, EBITDA up 11.8% to €743.9 million (38% margin), and adjusted net income up 10.7% to €493.1 million. Net income declined 3.6% to €326.3 million on non-cash charges linked to recent acquisitions and higher non-recurring items. The company expects full-year results in line with the lower half of its original guidance and will distribute an interim dividend of €0.63 per share. The headline strategic move: Recordati doubled the peak sales estimate for Isturisa to above €1.2 billion and will invest €40–50 million annually to expand into the “non-overt” Cushing’s syndrome population under its expanded U.S. label.
The pivot is telling. Recordati is converting a rare disease franchise into a broader cardiometabolic play, using label expansion and field activation rather than binary, high-risk R&D bets. The company projects that rare diseases will account for half of total revenue by 2026. That shift hinges on whether it can catalyze diagnosis and treatment in patients with mild hypercortisolemia who lack classic Cushingoid features but carry meaningful cardiovascular and metabolic risk. If the strategy lands, Recordati’s growth algorithm evolves from limited prevalence to addressable burden of disease; if it stalls, the company absorbs higher commercial and medical spend without the expected treatment expansion.
The business mix is moving in the right direction. Rare diseases grew 29.2% to €782.2 million, with endocrinology up 18.4% on U.S. Isturisa uptake and hematology-oncology up 71.4% as Enjaymo contributed €104 million and legacy assets Sylvant and Qarziba accelerated. Specialty and primary care rose 3.2% to €1.13 billion despite softer market growth in some geographies and currency headwinds. Free cash flow of €396.8 million was tempered by U.S. inventory build, while net debt stands at €2.03 billion, or 2.1x pro-forma EBITDA—leaving room for bolt-on business development.
For Medical Affairs, the Isturisa bet is a field execution challenge. The target prescribers expand to include tertiary endocrinologists, community endocrinologists, select primary care physicians, and cardiologists. That demands new diagnostic pathways, education on clinical thresholds, and tighter titration and safety monitoring. Payers will look beyond biochemical control to hard outcomes—blood pressure, glycemic control, and hospitalization rates—making the planned 2026 Phase IV study and a ramped real-world evidence program decisive for access and persistence. The opportunity is sizable—Recordati pegs the number of eligible U.S. patients rising from about 7,000 to roughly 30,000—but unlocking it will require guideline nudges, streamlined testing, and clear prior-authorization logic to avoid friction.
Competition, the Cushing’s therapy landscape remains fragmented across steroidogenesis inhibitors and glucocorticoid receptor modulators. Success in the non-overt population will likely be shaped by tolerability, dose management, and outcomes data that resonate with cardiometabolic stakeholders. Recordati’s multi-asset rare disease engine is also broadening. A potential U.S. pathway for Qarziba is now more straightforward, and the company is advancing targeted lifecycle programs, while the Vazkepa deal in 59 countries extends its cardiovascular footprint. Vazkepa’s near-term impact is modest and reimbursement remains variable, but the asset aligns with Recordati’s strategy at the endocrine–cardiometabolic intersection.
The next 12 months will test whether commercial scale, RWE velocity, and payer engagement can translate an expanded label into a step change in treated prevalence. Suppose Recordati proves that early, non-overt hypercortisolemia can be systematically identified and economically treated. In that case, it may set a playbook for European mid-cap specialists: grow rare disease franchises not just through acquisition, but by redefining the perimeter of treatable disease.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
